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Background
Potency of the cell-mediated immune response is now the
critical metric for down-selection of candidate HIV-1 vac-
cines. Here we characterize the potency (magnitude and
quality) of cell-mediated immunity generated in response
to a multigenic rMVA-based HIV-1 (CRF01_AE-derived)
vaccine.
Methods
49 healthy, vaccinia-naive volunteers were enrolled in a
phase I randomized, double-blind, dose-escalation,
route-comparison, placebo-controlled trial to assess the
safety and immunogenicity of MVA-CMDR HIV-1 vac-
cine. The study was divided into Part A: low-dose 106/pfu
ID versus 107 pfu/IM and Part B: high-dose 107 pfu/ID vs
108 pfu/IM. Vaccinations were given at months 0, 1 and 3
with an active:placebo ratio of 10:2. Chromium-release
CTL, IFNγ Elispot, and polyfunctional flow cytometry (IL-
2/IFNγ/TNFα/MIP-1β/CD107a), were performed on all
volunteers. Synthetic peptide pools and GLP-grade MVA
were used to assess insert (Gag/Pol/Env) and vector
immunogenicity respectively.
Results
Vector-specific responses were robust (> 80% response
rate at high-dose), durable (maintained at least 6
months), and exhibited a dose-dependent increase in
both magnitude and response rate among the 4 arms of
the trial. HIV-insert-specific responses were detected using
all assay platforms, but were lower than the vector-specific
responses in both magnitude and response rate in all arms
of the trial (~60% at high-dose by CTL, Elispot and ICS
assays). Specifically, polyfunctional analysis revealed a
TNFα/IL-2/IFNγ bias in CD4+ T cells and a MIP-1β/
CD107a/IFNγ bias in CD8+ T cells, with CD4+ T cell
responses more frequent than CD8+ T cell responses to
the HIV inserts. Vector-specific immune responses
showed a boosting effect from the 2nd to the 3rd immu-
nization.
Conclusion
rMVA vaccination induces a dose-dependent, robust and
durable polyfunctional cellular immune response as
measured by IFNγ Elispot, CTL and intracellular cytokine
stimulation assays. Although vector-specific responses
tend to dominate over insert-specific responses, the data
supports further exploration of MVA as a vector modality
in prime-boost vaccination strategies.
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